For the quarter ended March 2026, AbbVie (ABBV Quick QuoteABBV - Free Report) reported revenue of $15 billion, up 12.4% over the same period last year. EPS came in at $2.65, compared to $2.46 in the year-ago quarter.

The reported revenue represents a surprise of +1.47% over the Zacks Consensus Estimate of $14.78 billion. With the consensus EPS estimate being $2.62, the EPS surprise was +1.3%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenue- Humira- US: $357 million versus the four-analyst average estimate of $385.55 million. The reported number represents a year-over-year change of -52%.
• Net Revenue- Humira- International: $331 million compared to the $311.6 million average estimate based on four analysts. The reported number represents a change of -12.2% year over year.
• Net Revenue- Oncology- Elahere- Total: $198 million versus $205.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
• Net Revenue- Epkinly- U.S: $25 million versus $30.83 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.1% change.
• Net Revenue- Venclexta: $770 million versus the four-analyst average estimate of $718.62 million. The reported number represents a year-over-year change of +15.8%.
• Net Revenue- Humira: $688 million compared to the $696.9 million average estimate based on four analysts. The reported number represents a change of -38.6% year over year.
• Net Revenues- Neuroscience- Vyalev: $201 million compared to the $200.75 million average estimate based on four analysts.
• Net Revenue- Neuroscience- Total: $2.88 billion versus the four-analyst average estimate of $2.83 billion. The reported number represents a year-over-year change of +26%.
• Net Revenue- Immunology- Total: $7.29 billion compared to the $7.2 billion average estimate based on four analysts. The reported number represents a change of +16.4% year over year.
• Net Revenue- Hematologic Oncology- Total: $1.63 billion versus the four-analyst average estimate of $1.57 billion. The reported number represents a year-over-year change of -0.1%.
• Net Revenue- Botox Therapeutic- Total: $1.01 billion versus $989.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +16.5% change.
• Net Revenue- Vraylar- Total: $905 million versus $890.26 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +18.3% change.

View all Key Company Metrics for AbbVie here>>>

Shares of AbbVie have returned -9.1% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.